比较临床试验与真实世界无进展生存数据的恰当统计推断框架
针对外部时间至事件数据依赖疾病评估计划(DAS)且不同数据来源DAS不一致的问题,提出通过多重插补数据增广协调DAS的统计推断框架,模拟显示该框架估计中位TTE和风险比无偏、控制I类错误且对数秩检验把握度理想,推荐用于使用外部DAS依赖TTE数据的比较分析。
要点
- 不同数据来源的疾病评估计划(DAS)通常不一致,影响外部时间至事件数据比较。
- 提出通过多重插补数据增广协调DAS的统计推断框架。
- 模拟显示该框架估计中位TTE和风险比无偏,并良好控制I类错误与把握度。
核心结论
- 所提出的通过多重插补数据增广协调DAS的统计推断框架在估计中位TTE和风险比时无偏,并良好控制I类错误、对数秩检验获得理想把握度。
- 未校正分析可能产生偏倚,并依偏倚方向出现严重的I类错误膨胀或把握度损失。
- 鉴于该框架表现理想,推荐将其用于临床试验中使用外部DAS依赖TTE数据的比较分析。
研究设计与样本
- 方法学研究,提出通过数据增广(多重插补)协调疾病评估计划(DAS)的统计推断框架。
- 通过大量模拟评估所提框架与未校正分析在估计中位TTE、风险比、I类错误和对数秩检验把握度方面的表现。
主要发现
- 模拟显示所提框架估计中位TTE和风险比无偏,良好控制I类错误,对数秩检验获得理想把握度。
- 未校正分析可能产生偏倚,并依偏倚方向出现严重的I类错误膨胀或把握度损失。
临床怎么用
- 作者推荐将所提出的框架用于临床试验中使用外部DAS依赖TTE数据的比较分析。
局限性
- 原文指出该领域当前方法学开发聚焦于建立组间患者基线特征的可比性,还需更多研究确保其他要素(如终点)的可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The past decade has witnessed an increasing trend in utilizing external control data in clinical trials, especially in the form of synthetic control arms (SCA) derived from real-world or historical trial data. Including such data in clinical trial analysis can improve trial feasibility and efficiency, provided the issues caused by non-randomization and systematic differences are appropriately addressed. Current methodology development in this area focuses on establishing the comparability of patient baseline characteristics between arms, and more research is needed to ensure comparability of other elements such as endpoints. Motivated by the comparative analysis of SCA progression-free survival (PFS) and trial arm PFS, we aim to address another important but little discussed issue for external time-to-event (TTE) data that depend on disease assessment schedules (DAS). Since DAS are generally inconsistent across different data sources, we propose a proper statistical inference framework that harmonizes the DAS through data augmentation by multiple imputation. We demonstrate through extensive simulations that the proposed framework is unbiased in estimating median TTE and hazard ratio, well controls the type I error and achieves desirable power for log-rank test, while the unadjusted analysis can be biased and suffer from severe type I error inflation or power loss depending on the direction of the bias. Given the desirable performance, we recommend the proposed framework for comparative analysis using external DAS-based TTE data in clinical trials.
引用
- Zhu J, Tang RS. A proper statistical inference framework to compare clinical trial and real-world progression-free survival data. Stat Med. 2022. PMID: 36199170. doi:10.1002/sim.9590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。